Virus and Vaccinations
- Title
- Virus and Vaccinations
- Creator
- Abraham Hernandez
- Publisher
- Abraham Hernandez
- Date
- August 4, 2024
- Contributor
- Abraham Hernandez
- Rights
- CC-BY-NC-SA 4.0
- Type
- Images
Dublin Core
Collection Items
-
Ultrastructural Morphology of Coronaviruses.
This illustration reveals ultrastructural morphology exhibited by coronaviruses. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). -
COVID-19 Boosters and Updated Vaccines
UTSW researchers' findings suggest that COVID-19 boosters and updated vaccines are more important for older adults, who are more susceptible to severe illness with the virus. -
COVID-19 Test Performed at Toronto's Pearson International Airport
A COVID-19 test is performed at Toronto's Pearson International Airport. Ontario is moving away from the mass testing regime it has been running for most of the COVID-19 pandemic. -
Abbott Laboratories’ BinaxNOW At-Home COVID-19 Test
Abbott Laboratories’ BinaxNOW is one of at least 14 at-home antigen COVID-19 tests authorized for over-the-counter sale by the Food and Drug Administration -
Global COVID-19 Cases by Country
The image shows the number of COVID-19 cases throughout the world by country. -
Versions of the Virus and Mutation Pace
Versions of the virus today essentially are the same as the first one that was detected in December. And SARS-CoV-2’s sluggish pace of mutation is good news for us. -
CDC Identified Variants of Concern
The CDC has identified four "variants of concern," which are variants whose mutations significantly alter the virus’s ability to infect cells, enhance viral transmissibility, or cause more severe illness. These include alpha, beta, gamma, and delta. -
Covid Booster Shots
A line up of four different types of booster shots available to combat covid-19. -
The Alpha Variation
The alpha variant was first identified in the United Kingdom. The variant's attributes include 50% increased transmission, potential increased severity, (based on hospitalizations and case fatality rates). No impact on susceptibility to emergency use authorization (EUA) monoclonal antibody treatments. Minimal impact on neutralization by convalescent and post-vaccination sera.